FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519782392> ?p ?o ?g. }

• W2519782392 endingPage "179" @default.
• W2519782392 startingPage "172" @default.
• W2519782392 abstract "Background: Oncology therapy typically involves drug combinations since monotherapy seldom provides the desired outcome. But combination therapy presents the potential for drug-drug interactions (DDIs). Due to the narrow window between therapeutic concentrations and onset of toxicity often observed with oncology therapeutics, managing DDIs with combination therapy in cancer is critical. Physiologically based pharmacokinetic (PBPK) modeling can be effectively used for predicting DDIs and guiding dose-selection, but requires development of PBPK models of cancer drugs. Among various types of cancer, metastatic prostate cancer is an area of high unmet medical need with minimal therapeutic options. Recently, enzalutamide was approved for treatment of metastatic prostate cancer and is often dosed as a combination in clinical practice. Enzalutamide is a potent CYP3A inducer and a model-based approach to guide dose-selection for enzalutamide combinations that are CYP3A substrates is needed. Objective: A “fit for purpose” PBPK model of enzalutamide was developed to illustrate the CYP3A4 induction potential, understand the kinetics of de-induction of CYP3A4 following cessation of enzalutamide dosing and guide dose-selection of a co-administered CYP3A substrate. Method: The population-based simulator, Simcyp, was used for model building purposes. Model input parameters were obtained from public information, primarily from the FDA summaries. Results: The simulated concentration time profiles of enzalutamide in healthy male subjects were comparable to observed profiles in male patients. Model predicted enzalutamide pharmacokinetic (PK) parameters, i.e. AUC, Cmax and half-life were within 1.5-fold of observed results obtained from two reported studies, supporting verification of the PBPK model. Model application was demonstrated by simulating a drug-drug interaction between enzalutamide and midazolam, a sensitive CYP3A4 substrate. Based on simulations, the midazolam AUC ratio ranged from 0.06 to 0.16 and was comparable to the observed ratio of 0.14. Based on modeling, upon cessation of enzalutamide dosing, it is predicted that at least 8 weeks are needed to re-attain baseline CYP3A4 activity. Based on PBPK modeling, dose adjustment of up to 3-fold for a co-administered CYP3A substrate was shown to re-attain baseline exposure. Conclusion: A “fit for purpose” PBPK model of enzalutamide was successfully developed using public information that recapitulated it’s observed pharmacokinetics, CYP3A4 induction potential and the potential need for dose-adjustment of co-administered CYP3A substrates. Keywords: Cytochrome P450, drug-drug interaction, enzalutamide, enzyme induction, physiologically based pharmacokinetic model." @default.
• W2519782392 created "2016-09-23" @default.
• W2519782392 creator A5015098235 @default.
• W2519782392 creator A5024862572 @default.
• W2519782392 creator A5038853688 @default.
• W2519782392 creator A5086143640 @default.
• W2519782392 date "2016-09-29" @default.
• W2519782392 modified "2023-09-25" @default.
• W2519782392 title "Application of a “Fit for Purpose” PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide" @default.
• W2519782392 doi "https://doi.org/10.2174/1872312810666160729124745" @default.
• W2519782392 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27604990" @default.
• W2519782392 hasPublicationYear "2016" @default.
• W2519782392 type Work @default.
• W2519782392 sameAs 2519782392 @default.
• W2519782392 citedByCount "8" @default.
• W2519782392 countsByYear W25197823922017 @default.
• W2519782392 countsByYear W25197823922018 @default.
• W2519782392 countsByYear W25197823922020 @default.
• W2519782392 countsByYear W25197823922022 @default.
• W2519782392 crossrefType "journal-article" @default.
• W2519782392 hasAuthorship W2519782392A5015098235 @default.
• W2519782392 hasAuthorship W2519782392A5024862572 @default.
• W2519782392 hasAuthorship W2519782392A5038853688 @default.
• W2519782392 hasAuthorship W2519782392A5086143640 @default.
• W2519782392 hasConcept C109650736 @default.
• W2519782392 hasConcept C112705442 @default.
• W2519782392 hasConcept C11824378 @default.
• W2519782392 hasConcept C121608353 @default.
• W2519782392 hasConcept C126322002 @default.
• W2519782392 hasConcept C143998085 @default.
• W2519782392 hasConcept C185867374 @default.
• W2519782392 hasConcept C2776551883 @default.
• W2519782392 hasConcept C2780192828 @default.
• W2519782392 hasConcept C2781190966 @default.
• W2519782392 hasConcept C526171541 @default.
• W2519782392 hasConcept C61367390 @default.
• W2519782392 hasConcept C62231903 @default.
• W2519782392 hasConcept C71924100 @default.
• W2519782392 hasConcept C98274493 @default.
• W2519782392 hasConceptScore W2519782392C109650736 @default.
• W2519782392 hasConceptScore W2519782392C112705442 @default.
• W2519782392 hasConceptScore W2519782392C11824378 @default.
• W2519782392 hasConceptScore W2519782392C121608353 @default.
• W2519782392 hasConceptScore W2519782392C126322002 @default.
• W2519782392 hasConceptScore W2519782392C143998085 @default.
• W2519782392 hasConceptScore W2519782392C185867374 @default.
• W2519782392 hasConceptScore W2519782392C2776551883 @default.
• W2519782392 hasConceptScore W2519782392C2780192828 @default.
• W2519782392 hasConceptScore W2519782392C2781190966 @default.
• W2519782392 hasConceptScore W2519782392C526171541 @default.
• W2519782392 hasConceptScore W2519782392C61367390 @default.
• W2519782392 hasConceptScore W2519782392C62231903 @default.
• W2519782392 hasConceptScore W2519782392C71924100 @default.
• W2519782392 hasConceptScore W2519782392C98274493 @default.
• W2519782392 hasIssue "3" @default.
• W2519782392 hasLocation W25197823921 @default.
• W2519782392 hasOpenAccess W2519782392 @default.
• W2519782392 hasPrimaryLocation W25197823921 @default.
• W2519782392 hasRelatedWork W2000200648 @default.
• W2519782392 hasRelatedWork W2004439498 @default.
• W2519782392 hasRelatedWork W2021250530 @default.
• W2519782392 hasRelatedWork W2135620818 @default.
• W2519782392 hasRelatedWork W2568045406 @default.
• W2519782392 hasRelatedWork W2770702948 @default.
• W2519782392 hasRelatedWork W3043458966 @default.
• W2519782392 hasRelatedWork W3080423469 @default.
• W2519782392 hasRelatedWork W4206966109 @default.
• W2519782392 hasRelatedWork W4229076799 @default.
• W2519782392 hasVolume "10" @default.
• W2519782392 isParatext "false" @default.
• W2519782392 isRetracted "false" @default.
• W2519782392 magId "2519782392" @default.
• W2519782392 workType "article" @default.